Peptide Association
Start Your Consultation
All peptides
HormoneFDA Approved

PT-141 (Bremelanotide / Vyleesi)

Subcutaneous injection (as needed)
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A synthetic cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 works centrally through hypothalamic melanocortin pathways that modulate sexual arousal and desire.

Mechanism of Action

It is a metabolite of Melanotan II without significant melanogenic activity.

Research Summary & Key Findings

FDA-approved in 2019 (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. RECONNECT trials showed statistically significant increases in sexual desire and reduction in distress. First centrally-acting treatment for female sexual dysfunction.

Clinical Status

FDA Approved

PT-141 (Bremelanotide / Vyleesi) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (as needed)

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Hormone

CJC-1295

In Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...

View details

Ipamorelin

In Clinical Trials

A highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...

View details

Sermorelin

FDA Approved

A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...

View details

Tesamorelin (Egrifta)

FDA Approved

A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...

View details

Start Your Consultation

Get an AI-proposed PT-141 (Bremelanotide / Vyleesi) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply PT-141 (Bremelanotide / Vyleesi).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.